Search results
Showing 3451 to 3500 of 3765 results for treatment
This guideline covers support for adults (aged 18 and over) who provide unpaid care for anyone aged 16 or over with health or social care needs. It aims to improve the lives of carers by helping health and social care practitioners identify people who are caring for someone and give them the right information and support. It covers carers’ assessments, practical, emotional and social support and training, and support for carers providing end of life care.
NICE has developed a medtech innovation briefing (MIB) on the needle-free arterial non-injectable connector .
In development Reference number: GID-TA11274 Expected publication date: TBC
Learn about our role in the new international Health Economics Methods Advisory (HEMA) and its ambitions to make a real difference to patients around the world.
Biographies for all current members of the diagnostics advisory committee.
The appraisal has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.
The guidance has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.
Discontinued Reference number: GID-TA10566
Research to access pathway for investigational drugs for COVID-19 (RAPID C-19)
RAPID C-19’s role in reviewing potential COVID-19 treatments has now ended because we have moved back to routine commissioning arrangements for these treatments.
Find out more about NICE technology appraisals advisory committee D members
The Arrow OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy (MIB19)
NICE has developed a Medtech Innovation Briefing (MIB) on the ARROW OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy
Artificial intelligence (AI) and digital regulations service
We're playing a leading role in the AI and digital regulations service which supports the development and adoption of AI and data-driven technologies in health and care.
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
In development Reference number: GID-TA11086 Expected publication date: TBC
For more than 25 years NICE has helped practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.
First HIV prevention injection for people unable to have daily PrEP recommended
A ground-breaking HIV-1 prevention injection has been recommended by NICE, marking a significant advance for a small group of adults and young people unable to have daily pre-exposure prophylaxis (PrEP) tablets.
We explore the ongoing debate around NICE’s cost-effectiveness thresholds and what the future holds.
treating osteoporosis Digestive tract conditions Long term heartburn treatment Gynaecological conditions and abortion Menopause: HRT and...
Biographies and registered interests for members of the Technology Appraisal Committee C
This guideline covers support for disabled children and young people with severe complex needs, from birth to 25 years. It aims to encourage education, health and social care services to work together and provide more coordinated support to children and young people, and their families and carers.
Show all sections
Sections for NG213
- Overview
- Recommendations on support for all disabled children and young people with severe complex needs
- Recommendations on specialist support for disabled children and young people with particular needs
- Recommendations on service organisation, integration and commissioning
- Terms used in this guideline
- Recommendations for research
- Rationale and impact for recommendations on supporting all disabled children and young people with severe complex needs
- Rationale and impact for recommendations on specialist support for disabled children and young people with particular needs
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
Biographies and registered interests for members of the Technology Appraisal Committee A
Tackling variation in rehab for people with neurological conditions
NICE has recommended a standardised approach for rehabilitation, to address the variation of care experienced by millions of people with chronic neurological conditions.
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Technology appraisal and highly specialised technologies appeals
Learn about the NICE Technology Appraisal and Highly Specialised Technologies appeals process, including how decisions are made, the criteria for appeals, and the role of the appeal panel in ensuring fair and transparent evaluations of health technologies.
NICE joins international collaboration on HTA methods research
We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new international initiative to research and evaluate health technology assessment (HTA) methods.
Our chief executive, Dr Sam Roberts, welcomes the government's 10 Year Plan for healthcare
The government's 10 Year Plan marks a pivotal moment for healthcare and strengthens NICE’s role.
Data on the recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
Our first guideline on kidney cancer recommends better use of biopsies to avoid surgery
New guidance aims to reduce variation in treatment and prevent unnecessary surgery, improving care for patients and supporting healthcare professionals.
Engage at the optimal time for your technology appraisal, to achieve NICE guidance at the same time as marketing authorisation.
NICE has a key role in UK licensing and the evaluation of and access to new and innovative products for the health system.
NICE has been working in partnership with the London School of Economics and Political Science (LSE) to jointly develop and deliver an Executive MSc in Healthcare Decision-Making. Discover how this advanced healthcare training bridges clinical practice and system-wide decision-making through one committee member's transformative journey.
The new approach puts HealthTech on equal footing with medicines, ensuring innovations like wearable diabetes monitors and AI diagnostics reach patients faster and more consistently across the NHS.
Hundreds of people set to benefit after life-extending lung cancer treatment given green light
Targeted immunotherapy found to significantly increase overall survival rates for people with an aggressive form of lung cancer has been recommended by NICE.
promotion of good health the prevention of ill health the appropriate treatment and care for people with specific diseases and...
NICE is committed to supporting the national agenda for achieving a sustainable health and care system.
think about the impact on those whose treatment or care may be displaced as a result of additional spending on treatments...
Breakthrough life-extending combination treatment for advanced bladder cancer recommended by NICE
The new treatment offers hope to thousands living with advanced urothelial cancer, with clinical trials showing overall survival rates were almost twice as long compared to standard treatment.
We assess the efficacy and safety of interventional procedures used for treatment or diagnosis to determine whether they work well enough and are safe enough for use in the NHS.
A timeline showing where in the NICE evaluation process companies will be charged.
Our modular updates framework ensures flexibility and consistency in updating our manuals and helps prioritise important updates.
International collaboration with NICE
Biggest shake-up in type 2 diabetes care in a decade announced
Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority clinical pathways described in the 10-Year Health Plan for the NHS.
Recommendations in NICE’s type 2 diabetes guideline update, published today, will enhance the use of SGLT-2 inhibitors in primary care and address these health inequalities.
IMI and H2020 Grant funded projects with NICE
People coming off obesity medication or finishing a weight management programme should be offered support to help keep the weight off and stay healthy long-term, according to our updated quality standard.
Technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.
Hypertension case finding and optimal management and lipid optimal management
prematurely by ensuring people have better access to flexible, well-coordinated treatment and support. Hypertension in adults: diagnosis...
Our stakeholders are involved in the development of NICE guidance and quality standards to ensure that the recommendations are relevant, practical, and meet the needs of those affected by the health or social care issues addressed.
Information and benefits about shared decision making. Includes links to patient decision aids.